Symbolbild · KI-generiert
Profound Medical Corp.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, TULSA-PRO ®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure¿ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care-from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. Profound also commercializes Sonalleve ®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Profound Medical Corp. | PRN | TSX | 269 Mio. USD |
| Myriad Genetics, Inc. | MYGN | NASDAQ | 270 Mio. USD |
| Spectral Medical Inc. | EDT | TSX | 291 Mio. USD |
| Neumora Therapeutics, Inc. | NMRA | NASDAQ | 298 Mio. USD |
| Cipher Pharmaceuticals Inc. | CPH | TSX | 305 Mio. USD |
| Organogenesis Holdings Inc. | ORGO | NASDAQ | 305 Mio. USD |
| Opus Genetics, Inc. | IRD | NASDAQ | 306 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.